Supply of Ozempic and other GLP-1 receptor agonists: Notice

Date published: April 6, 2023
Date updated: June 4, 2024

On this page

• About GLP-1 receptor agonists
• What we're doing
• Recommendations for patients

About GLP-1 receptor agonists

Glucagon-like peptide-1 (GLP-1) and dual GLP-1/GIP (glucose-dependent insulintropic polypeptide) receptor agonists are used to treat adult patients with type 2 diabetes mellitus. We have seen high demand around the world, including in Canada.

Supply issues have affected the following products:

• Ozempic (Semaglutide), a GLP-1
• Trulicity (dulaglutide), a GLP-1
• Mounjaro (tirzepatide), a dual GLP-1/GIP

Health Canada recognizes the importance of these products for people in Canada. Addressing this issue is a top priority.

What we're doing

Health Canada is working with manufacturers, distributors and stakeholders to monitor supply. We're also looking at how these products can be made more available.

We have engaged groups representing health care providers and patients, such as Diabetes Canada, Diabète Québec and Obesity Canada. We're also communicating with the provincial and territorial governments and regulators in other impacted countries.

We will update this web page when we have new information to share.

Recommendations for patients

You should contact your pharmacy well before your current supply will run out.

If you have questions or concerns about any of these drugs, speak to a health care provider, such as your doctor or pharmacist.

Note: The practice of pharmacy and medicine is overseen by professional colleges in each province and territory.